KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to 0.11.

  • Inovio Pharmaceuticals' Equity Ratio fell 11619.75% to 0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11, marking a year-over-year decrease of 11619.75%. This contributed to the annual value of 0.61 for FY2024, which is 1184.0% down from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Equity Ratio stood at 0.11 for Q3 2025, which was down 11619.75% from 0.42 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Equity Ratio ranged from a high of 0.89 in Q1 2021 and a low of 0.11 during Q3 2025
  • Over the past 5 years, Inovio Pharmaceuticals' median Equity Ratio value was 0.72 (recorded in 2023), while the average stood at 0.67.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 10434.43% in 2021, then tumbled by 11619.75% in 2025.
  • Inovio Pharmaceuticals' Equity Ratio (Quarter) stood at 0.81 in 2021, then dropped by 20.83% to 0.64 in 2022, then grew by 7.59% to 0.69 in 2023, then dropped by 11.84% to 0.61 in 2024, then plummeted by 118.39% to 0.11 in 2025.
  • Its Equity Ratio was 0.11 in Q3 2025, compared to 0.42 in Q2 2025 and 0.59 in Q1 2025.